Literature DB >> 1951297

Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2).

E E Mast1, M W Harmon, S Gravenstein, S P Wu, N H Arden, R Circo, G Tyszka, A P Kendal, J P Davis.   

Abstract

Outbreaks of influenza A (H3N2, A/Shanghai/11/87-like) occurred in two partially (60% and 79%) vaccinated nursing home populations in January 1988. A retrospective cohort study using chart review was designed to assess the effectiveness of influenza vaccination and amantadine prophylaxis (100 mg per day) in controlling the outbreaks and to determine the amantadine susceptibility of influenza viruses isolated from case-patients. The point estimate of vaccine efficacy in preventing influenza-like illness was -33% (95% confidence interval -115% to 18%). However, 9% of vaccinated case-patients died within 14 days after onset of influenza-like illness compared with 26% of unvaccinated case-patients (relative risk = 0.4, 95% confidence interval 0.1-1.0). There was no significant difference in illness severity among case-patients who became ill before amantadine prophylaxis was started (n = 84) compared with those who became ill while taking amantadine (n = 34). Four virus isolates obtained before amantadine prophylaxis was started demonstrated 52-68% inhibition by 1 microgram/ml of amantadine; by comparison, six isolates (resistant viruses) obtained from residents who became ill while taking amantadine demonstrated 1-18% inhibition. The resistant viruses had four different RNA sequences in the gene coding for the M2 protein transmembrane region. Three resistant viruses with identical RNA sequences were isolated from residents living in contiguous rooms who had onset of signs and symptoms during a 6-day interval. Further studies are needed to determine how frequently and under what circumstances resistant viruses occur when antiviral agents are used to control institutional influenza A outbreaks. Strategies for antiviral agent administration that limit the emergence and transmission of resistant virus strains may be needed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1951297     DOI: 10.1093/oxfordjournals.aje.a116184

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  22 in total

1.  Isolation of amantadine-resistant influenza a viruses (H3N2) from patients following administration of amantadine in Japan.

Authors:  J Iwahashi; K Tsuji; T Ishibashi; J Kajiwara; Y Imamura; R Mori; K Hara; T Kashiwagi; Y Ohtsu; N Hamada; H Maeda; M Toyoda; T Toyoda
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

Review 2.  Oseltamivir: a review of its use in influenza.

Authors:  K McClellan; C M Perry
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2.

Authors:  Reiko Saito; Takatsugu Sakai; Isamu Sato; Yasuko Sano; Hitoshi Oshitani; Mizuho Sato; Hiroshi Suzuki
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

4.  Use of antiviral prophylaxis in influenza outbreaks in long term care facilities.

Authors:  A McGeer; D S Sitar; S E Tamblyn; K Faron; P Orr; F Y Aoki
Journal:  Can J Infect Dis       Date:  2000-07

5.  The use of antiviral drugs for influenza: recommended guidelines for practitioners.

Authors:  Upton D Allen; Fred Y Aoki; H Grant Stiver
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

6.  Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.

Authors:  S Bantia; A A Ghate; S L Ananth; Y S Babu; G M Air; G M Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 7.  The influenza pandemic of 2009: lessons and implications.

Authors:  Paul Shapshak; Francesco Chiappelli; Charurut Somboonwit; John Sinnott
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

8.  Amantadine use in influenza outbreaks in long-term care facilities.

Authors:  S E Tamblyn
Journal:  CMAJ       Date:  1997-12-01       Impact factor: 8.262

9.  Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.

Authors:  J L McKimm-Breschkin; T J Blick; A Sahasrabudhe; T Tiong; D Marshall; G J Hart; R C Bethell; C R Penn
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

10.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.